Patents by Inventor Matthew J. Sharp

Matthew J. Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABIRATERONE PRODRUGS
    Publication number: 20260014172
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: September 17, 2025
    Publication date: January 15, 2026
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY
    Publication number: 20250186463
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a human subject having a sex hormone-dependent or androgen receptor driven disease or disorder, such as a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, and/or a syndrome due to androgen excess.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 12, 2025
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • ABIRATERONE PRODRUGS
    Publication number: 20250099489
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: October 18, 2024
    Publication date: March 27, 2025
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • ORAL ABIRATERONE FORMULATIONS
    Publication number: 20250025417
    Abstract: Provided herein are oral abiraterone prodrug formulations, related methods and kits, for example, for oral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: September 7, 2022
    Publication date: January 23, 2025
    Inventors: Matthew J. SHARP, William R. MOORE
  • Abiraterone prodrugs
    Patent number: 12138273
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: November 12, 2024
    Assignee: PROPELLA THERAPEUTICS, INC.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • ABIRATERONE PRODRUGS
    Publication number: 20240139212
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: July 26, 2023
    Publication date: May 2, 2024
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • Abiraterone prodrugs
    Patent number: 11957696
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: April 16, 2024
    Assignee: PROPELLA THERAPEUTICS, INC.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • ABIRATERONE PRODRUGS
    Publication number: 20240050447
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 15, 2024
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • ABIRATERONE PRODRUGS
    Publication number: 20230233582
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 27, 2023
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • Abiraterone prodrugs
    Patent number: 11559534
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 24, 2023
    Assignee: Propella Therapeutics, Inc.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • ABIRATERONE PRODRUGS
    Publication number: 20220265681
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: February 14, 2022
    Publication date: August 25, 2022
    Inventors: Matthew J. SHARP, William R. Moore, JR.
  • TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF
    Publication number: 20220249496
    Abstract: Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 11, 2022
    Inventor: Matthew J. SHARP
  • Topical acyclovir formulations and uses thereof
    Patent number: 11246872
    Abstract: Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 15, 2022
    Assignee: Propella Therapeutics, Inc.
    Inventor: Matthew J. Sharp
  • TOPICAL ACYCLOVIR FORMULATIONS AND USES THEREOF
    Publication number: 20200390773
    Abstract: Provided herein are gel formulations of acyclovir with a low concentration of acyclovir, which can be used, for example, for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. The gel formulation can be an aqueous gel formulation, an emulsified gel formulation, or a non-aqueous gel formulation.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Inventor: Matthew J. Sharp
  • ABIRATERONE PRODRUGS
    Publication number: 20200368255
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 26, 2020
    Inventors: Matthew J. SHARP, William R. Moore, JR.
  • Abiraterone prodrugs
    Patent number: 10792292
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 6, 2020
    Assignee: Propella Therapeutics, Inc.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • ABIRATERONE PRODRUGS
    Publication number: 20200281945
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Application
    Filed: March 4, 2020
    Publication date: September 10, 2020
    Inventors: Matthew J. SHARP, William R. MOORE, JR.
  • Novel anti-infectives
    Publication number: 20040147739
    Abstract: Compounds useful as HCV anti-infectives having the formula: wherein the formula variables are as defined herein, are disclosed. Also disclosed are methods of making and using the same.
    Type: Application
    Filed: December 2, 2003
    Publication date: July 29, 2004
    Inventors: Deping Chai, Michael G. Darey, Dashyant Dhanak, Kevin J. Duffy, Greg A. Erickson, Duke M. Fitch, Adam T. Gates, Victor K. Johnston, Robert T. Sarisky, Matthew J. Sharp, Antony N. Shaw, Rosanna Tedesco, Kenneth J. Wiggall, Michael N. Zimmerman
  • Synthesis of 6-azaandrostenones
    Patent number: 5541322
    Abstract: A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) ##STR1## wherein the substituents are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: July 30, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Francis G. Fang, Matthew J. Sharp